The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Open accessAbstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,246
Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus
Glezen, W. P. (1986) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1986.02140200053026 · Cited by 1,527
IgG placental transfer in healthy and pathological pregnancies
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., & Carneiro-Sampaio, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/985646 · Cited by 1,037
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Kampmann, B., Madhi, S. A., Munjal, I., Simões, E. A. F., Pahud, B. A., Llapur, C., Baker, J., Pérez Marc, G., Radley, D., Shittu, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2216480 · Cited by 1,004
Feltes, T. F., Cabalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top, F. H., Connor, E. M., Sondheimer, H. M., & for the Cardiac Synagis Study Group (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00454-2 · Cited by 824
Melgar, M., Britton, A., Roper, L. E., Talbot, H. K., Long, S. S., Kotton, C. N., & Havers, F. P. (2023) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7229a4 · Cited by 328
Self-citationRosas-Salazar, C., Chirkova, T., Gebretsadik, T., Chappell, J. D., Peebles, R. S., Dupont, W. D., Jadhao, S. J., Gergen, P. J., Anderson, L. J., & Hartert, T. V. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00811-5 · Cited by 261
Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018
Hansen, C. L., Chaves, S. S., Demont, C., & Viboud, C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0527 · Cited by 251
Langley, G. F., & Anderson, L. J. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182184ae7 · Cited by 140
Cited by
Sallam, M., Kherfan, T., Al‐Farajat, A., Nemrawi, L., Atawneh, N., Fram, R., Al‐Tammemi, A. B., Barakat, M., & Fram, K. (2025) · Health Science Reports · doi:10.1002/hsr2.70319 · Cited by 12
Sauer, M. A., Fesshaye, B., Miller, E. S., Schue, J. L., Singh, P., Jalang’o, R., Nyiro, J., Karanja-Chege, C., Njogu, R., Were, F., et al. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004505
Metadata
- Authors
- Fleming-Dutra, K. E., Jones, J. M., Roper, L. E., Prill, M. M., Ortega-Sanchez, I. R., Moulia, D. L., Wallace, M., Godfrey, M., Broder, K. R., Tepper, N. K., Brooks, O., Sánchez, P. J., Kotton, C. N., Mahon, B. E., Long, S. S., & McMorrow, M. L.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2023-10-13
- Volume
- 72
- Issue
- 41
- Pages
- 1115-1122
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W4387399495
- Cited by
- 309
- References
- 13
- FWCI
- 51.68
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. https://app.cochat.ai/papers/10.15585/mmwr.mm7241e1
- The paper
- Fleming-Dutra, K. E., Jones, J. M., Roper, L. E., Prill, M. M., Ortega-Sanchez, I. R., Moulia, D. L., Wallace, M., Godfrey, M., Broder, K. R., Tepper, N. K., Brooks, O., Sánchez, P. J., Kotton, C. N., Mahon, B. E., Long, S. S., & McMorrow, M. L. (2023). Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7241e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.